MAPT and Alzheimer disease: In recent years, the “ATN” categorization, which is a framework for defining AD based on biomarker proxies of pathology, where A stands for amyloid-beta (Aβ) status, “T” for tau, and “N” for neurodegeneration biomarkers, has gained attention [1, 2].